URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.

Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) procedures in Arizona using the Vanquish® Water ...

While many people are familiar with mammograms and smear tests, prostate screening is talked about far less. To shed light on this important subject ahead of Prostate Cancer Awareness Month in March, ...

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

Tech tycoons, podcast bros and Hollywood stars are all piling money into full-body scans, which deploy AI in the hope of catching everything from high cholesterol to cancer. Is this the first step to ...

Overview of Ac‑225 PSMA therapy, what real patient cases can illustrate about the treatment pathway, and key steps for eligibility review and choosing a center.

Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...

Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...

Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26), taking place in London from 13–16 March 2026.

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.